TipRanks

aTyr Pharma (471) Stock Price & Analysis

471 Stock Chart & Stats

€0.23€0.00(0.00%)
At close: 1:00 AM GMT+1
€5€10€15€2010 Aug25 Sep27 Oct
Day’s Range
EUR 0.23 - EUR 0.23
52-Week Range
EUR 0.23 - EUR 32.00
Previous Close
EUR 0.23
Volume
N/A
Average Volume (3M)
8
Market Cap
EUR 10.85M
Enterprise Value
EUR 12.22M
Total Cash (Recent Filing)
EUR 57.42M
Total Debt (Recent Filing)
EUR 11.30M
Price to Earnings (P/E)
―
Beta
1.04
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-3.58
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FDA-aligned Phase 3 Program

FDA agreement on the Phase 3 protocol reduces regulatory uncertainty around efzofitimod’s next clinical step and establishes defined endpoints, enrollment, and timing. If execution is successful, the program could advance a differentiated therapy toward a meaningful unmet medical need.

Exclusive Global Efzofitimod Rights

Reclaiming exclusive worldwide rights gives aTyr direct control over efzofitimod’s development and commercialization strategy, while eliminating outstanding development cost payments from Kyorin. This concentrates future value and strategic flexibility in the company’s lead asset.

Modest Leverage

Relatively modest leverage limits the balance sheet burden from debt and preserves more flexibility than a heavily indebted structure would provide. This is a durable financial offset for a clinical-stage company, although it does not remove the need to fund ongoing development.

Bears Say

Persistent Cash Burn And Funding Dependence

Consistently negative operating and free cash flow means aTyr is not self-funding its research and development activities. Continued dependence on financing, partnerships, or other capital sources can constrain strategic choices and expose the company to funding risk while programs advance.

Minimal Revenue And Deep Losses

The absence of meaningful, stable revenue leaves aTyr reliant on clinical progress rather than commercial operations to build financial strength. Deep losses across periods reduce internal funding capacity and make sustained profitability dependent on successful development and eventual product traction.

Eroding Assets And Equity

Declining assets and equity indicate that ongoing losses are consuming the company’s capital base rather than generating returns. Unless operating results improve or new funding is secured, this erosion can reduce financial resilience and limit the resources available for clinical execution.

471 FAQ

What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was €0.23 and its highest was €32.00 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is €10.85M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 3 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Aug 07, 2026. The company reported -€3.94 earnings per share for the quarter, beating the consensus estimate of -€4.349 by €0.409.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -3.58.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 2,452,186 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -€3.94 in its last earnings report, beating expectations of -€4.349. Following the earnings report the stock price went up 45.21%.
Which hedge fund is a major shareholder of aTyr Pharma?
Hedge funds hold aTyr Pharma shares: the largest hedge-fund position in aTyr Pharma is 1,262,226,123 shares, and hedge funds decreased their holdings by 250.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology